⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of IXICO plc and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
IXICO plc
↗London, United Kingdom
IXICO is a specialist neuroscience imaging and digital biomarker analytics company that operates as an Imaging Contract Research Organisation (iCRO). The company provides AI-driven technology and scientific expertise to biopharmaceutical companies to support clinical trials in neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's disease.
Through its proprietary IXI™ platform, IXICO enables the processing and analysis of complex neuroimaging data (such as MRI and PET scans) to provide insights into drug safety, efficacy, and disease progression. The company is currently transitioning toward a 'TechBio' model, aiming to broaden its market by licensing its technology directly to external partners.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:CRO
Sub-Industry:Neuroimaging and Digital Biomarker Analytics
SIZE & FINANCIALS
Employees:51-200
Revenue:$10M-$20M
Founded:2004
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:LSE
Ticker:IXI
Market Cap:$0.025B
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service Provider)
Modalities:AI/Digital Health
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:IXICO Ltd
Key Partnerships:Medidata (Platform integration partnership)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Bram Goorden - CEO
Robin Wolz - Chief Scientific and Medical Officer
Tanya Voloshen - Chief Commercial Officer
Scientific Founders:Derek Hill, Daniel Rueckert, David Hawkes, Jo Hajnal
Board Members:Mark Warne (Chair), Dipti Amin, Kate Rogers
LINKS
Website:ixico.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with IXICO plc. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.